A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia

The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic myeloid leukemia and has been used in research studies. We developed a DNA real-time quantitative PCR (qPCR) method for quantification of BCR-ABL1 sequences, which is also potentially suitable for routine use. The BCR-ABL1 breakpoint was sequenced after isolation by nested short-range PCR of DNA from blood, marrow, and cells on slides, obtained either at diagnosis or during treatment, or from artificial mixtures.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular article Source Type: research

Related Links:

Abstract Our objective was to determine the association between the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) and the risk of developing acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and multiple myelomas (MM) in Latinos. PubMed, SCOPUS, EBSCO, LILACS, and other Latin-specific databases were searched for case-control studies that investigated the association between these polymorphisms and hematologic malignancies until November 2017. Genotype distributions were extracted and either fixed-effects or random-effects models were used to calculate t...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Conclusion.Planned pregnancy might be pragmatic in female patients with CML on TKIs. Achieving deep molecular response and, importantly, MMR duration ≥3.5 years were significantly associated with maintaining MMR during pregnancy.Implications for Practice.Female patients with chronic myeloid leukemia on tyrosine kinase inhibitors (TKIs) wishing to conceive are currently advised to discontinue TKIs before conception. However, the ideal degree and duration of response before stopping TKI, in addition to whether there will be any adverse effect caused by a short exposure of TKI, is unknown. Data of 17 female patients, who a...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Leukemias, Hematologic Malignancies Source Type: research
In this study, we show that different TKIs used for treatment of Chronic Myeloid Leukemia have opposing effects on platelet function, with large inter ‐individual differences. Thus, in patients with high risk for hemostatic or thrombotic complications, we suggest that treatment with TKIs should be individualized to minimize risks associated with long‐term treatment. AbstractSince their introduction, tyrosine kinase inhibitors (TKIs, eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) have revolutionized the treatment of chronic myeloid leukemia (CML). However, long ‐term treatment with TKIs is associated with s...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31714657 [PubMed - as supplied by publisher]
Source: Biomed Res - Category: Research Authors: Tags: J Biomed Mater Res A Source Type: research
Abstract Colorectal cancer (CRC) remains one of the most common gastrointestinal tumors, characterized by a poor survival rate. Effects of single use of homoharringtonine (HHT), approved for the treatment of acute myelocytic leukemia (AML) and chronic myeloid leukemia (CML), on CRC, are unknown. According to the TCGA database, EphB4 is aberrantly overexpressed in CRC patients. Therefore, the purpose of this study was to investigate the inhibitory effect of HHT on CRC and its underlying mechanism. HHT significantly suppressed LoVo cell growth in vitro and in vivo, and induced apoptosis and cell cycle arrest at the ...
Source: Food and Chemical Toxicology - Category: Food Science Authors: Tags: Food Chem Toxicol Source Type: research
Abstract The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the International Scale (qPCRIS). BCR-ABL1 has also been found in asymptomatic normal individuals using a non-qPCRIS method. In the present study, we examined the prevalence of BCR-ABL1 in a normal population in southern Sarawak by performing qPCRIS for BCR-ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. While 146 of 190 (76.8...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
Nilotinib, a tyrosine kinase inhibitor, used for the treatment of chronic myeloid leukemia (CML), is known to produce atherosclerotic complications such as coronary artery disease, peripheral artery disease [1] and intracranial arterial stenosis/occlusion (ICASO) [2,3]. Middle cerebral artery (MCA) is the most common site involved in ICASO in CML patients treated with nilotinib [2]. It has been remained unknown what factors influence the development of ICASO in patients treated with nilotinib. Because reported patients with ICASO were rare, there is a possibility that some specific factors such as genetic mutations are ass...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Publication date: Available online 7 November 2019Source: Journal of Chemical NeuroanatomyAuthor(s): Henrique J.C.B. Gouveia, Raul Manhães-de-Castro, Bárbara J.R. Costa-de-Santana, Carolina R. Mendonça, Glayciele Leandro de Albuquerque, Diego Bulcão Visco, Diego Cabral Lacerda, Ana Elisa ToscanoAbstractBusulfan is a bifunctional alkylating agent used for myeloablative conditioning and in the treatment of chronic myeloid leukemia due to its ability to cause DNA damage. However, in rodent experiments, busulfan presented a potential teratogenic and cytotoxic effect. Studies have evaluated the effec...
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor.  The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team ca...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Pathology | Study